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Flaxseed: A potential treatment for lupus nephritis. Flaxseed is rich in
a-linolenic acid (a-LA) which has anti-atherogenic properties, and lignans
which are platelet activating factor (PAF)-receptor antagonists. These
constituents of fiaxseed, and its beneficial effects in the MRL/lpr lupus
mouse prompted us to perform this dosing study in lupus nephritis
patients. Nine patients were enrolled, eight of whom completed the study.
After the baseline studies, patients were given 15, 30, and 45 g of
flaxseed/day sequentially at four week intervals, followed by a five-week
washout period. Compliance, disease activity, blood pressure, plasma
lipids, rheology, PAF-induced platelet aggregation, renal function, and
serum immunology were assessed. Flaxseed-sachet count and a significant
increase of serum a-LA indicated good compliance for 15 and 30 g doses.
Total and LDL cholesterol, and blood viscosity were significantly reduced
with 30 g and to a lesser extent 45 g doses. PAF-induced platelet
aggregation was inhibited by all doses. There was a significant decline in
serum creatinine with 30 and 45 g, and a concomitant increase in
creatinine clearance with increasing flaxseed dose. Proteinuria was re-
duced with 30 g and to a lesser extent with 45 g of flaxseed. Complement
C3 was significantly elevated by all three doses. CD11b expression on
neutrophils, a measure of C3bi receptors, was significantly reduced with
the 30 g dose. In conclusion, 30 g flaxseed/day was well tolerated and
conferred benefit in terms of renal function as well as inflammatory and
atherogenic mechanisms important in the pathogenesis of lupus nephritis.
Nutritional intervention in progressive kidney disease is under-
going a renaissance [1—5]. Our interest in omega-3 fatty acids led
us to carry out this current dosing study of flaxseed in patients
with lupus nephritis [6—10]. Flaxseed is a rich source of a-linolenic
acid (a-LA, 8:3n3). However, it is not only the anti-mitogenic and
lipid lowering qualities of the a-LA, but also the lignan content
with its potent PAF receptor antagonist properties that attracted
our interest [11—14]. PAF is a major participant in the activation
and propagation of the inflammatory reaction, and is known to be
elevated in patients and animals with lupus nephritis. PAF
inhibition in lupus animal models is associated with increased
survival and decreased proteinuria [15—18]. We recently reported
the effects of a 15% flaxseed diet in the MRLI1pr mouse model of
lupus nephritis [8]. The MRLI1pr mice spontaneously develop a
lymphoproliferative syndrome associated with a progressive sys-
temic autoimmune disease involving kidney, heart, skin and joints
similar to severe forms of human lupus nephritis [19]. The
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flaxseed significantly preserved GFR, reduced proteinuria, lym-
phoproliferation and mortality in the MRLIIpr model and was
much more potent than previous studies with fish oil [8]. We also
studied the effects of flaxseed versus its constituents (flax oil and
defatted flax) in the MRLI1pr mice, and observed that the whole
flaxseed conferred superior benefit compared to its oil or defatted
constituents [9]. These encouraging results prompted us to inves-
tigate the short term effects of three different doses of flaxseed on
immune, inflammatory, rheologic, platelet and lipid parameters in
lupus nephritis. We wished to determine a dose of flaxseed which
was well tolerated and would have a significant effect on patho-
genic mechanisms known to be involved in this progressive
scarring disorder.
Methods
Patients
Nine patients were recruited for this study. All patients met the
minimum American Rheumatism Association's criteria for the
diagnosis of systemic lupus erythematosus (SLE) and all had a
documented history of positive ANA, and at least one episode of
elevated anti-DNA binding with proteinuria > 1 g124 hours, red
cells and red cell casts on urinalysis [20]. Seven of the nine
patients also had undergone renal biopsy (Table 1). Eight patients
were receiving prednisone in doses ranging from 5 mg on alter-
nate days to 10 mg daily, and two were receiving Imuran.
Additional characteristics of the patients are provided in Table 1.
Trial design
The study was divided into four phases. The first three phases
were of four weeks duration and the last phase was of five weeks
duration. In phase 1 the subjects ingested 15 g of flaxseed daily
with cereal, tomato or orange juice and this was increased to 15 g
twice daily in the ensuing four weeks. In the final four weeks of
study the flaxseed was increased to 15 g thrice daily, and this was
followed by a five-week washout period.
Dietary intake assessment
A three-day dietary intake record was obtained from each
patient at each phase of the study and analyzed using the
Canadian Nutrient File Database (Nutrition Res. Div., Health
Protection Branch, Ottawa, ON, Canada). Total calories, protein,
fat, cholesterol, saturated fatty acids, monounsaturated fatty acids
and polyunsaturated fatty acids were calculated. In addition,
protein catabolic rate (PCR glday) was calculated from protein
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Table 1. Characteristics of the patients who completed the study
Patient
number
Age
years Gender
Length
of lupus
months
Renal
biopsy
classification
1 36 female 96 DPGN
2 43 female 8 FPGN
3 32 female 36 DPGN
4 35 female 122 DPGN
5 51 female 84 DPGN
6 72 male 84 DPGN
7 40 male 84 DPGN
8 47 female 36 DPGN
Mean age was 44.5 years; mean length with lupus was 68.8 months.
Biopsy classifications: are DPGN, diffuse proliferative; FPGN, focal
proliferative.
excretion, urea excretion and urea generation determination
according to Sargent and Gotch [21].
Compliance
Sachets containing 15 g of flaxseed were provided to each
patient. Extra sachets were given for each phase of the study.
Sachets returned at the end of each phase provided a measure of
flaxseed intake. However, the actual ingestion of flaxseed was
assessed from the relative increase of a-linolenic acid from the
fatty acid analyses of serum phospholipids.
Fatly acid contents of serum phospholipids
Serum phospholipids were extracted and assessed for fatty acids
as previously described [22]. In brief, the lipid extracts were
subjected to thin layer chromatography. The phospholipid bands
corresponding to different lipid fractions were isolated and as-
sessed for fatty acid composition using gas chromatography.
SLE Disease Activity Index
At each visit patients were assessed by the same physician who
scored the SLE Disease Activity Index (SLEDAI) [23].
Blood pressure
Supine and standing blood pressure was obtained by a mercury
sphygmomanometer and taking Korotkoff's fifth sound as the
diastolic blood pressure cut-off.
Plasma lipids
Fasting blood samples (12 to 14 hr) were collected in EDTA on
ice. Plasma was assayed for total triglycerides, total cholesterol,
HDL-, LDL-, and VLDL-cholesterol as previously described [22].
All assays were standardized to plasma secondary standards for
which the target values were assigned at the Lipid Research Clinic
Laboratory, University of Toronto (St. Michael's Hospital, To-
ronto, ON, Canada).
Rheology
The viscosity of heparinized whole blood relative to water was
measured using a white cell pipette at room temperature accord-
ing to the method of Wright and Jenkins [24]. For red cell
flexibility (RCF) heparinized blood was centrifuged for two
minutes in a Clay Adams Autocrit centrifuge (Clay Adams Co.,
Parsippany, NJ, USA) at 200 X g. The red cell flexibility was
measured as a percentage of cell packing/mm as outlined by Sirs
[25].
PAF-induced platelet aggregation
Platelet rich plasma was prepared from citrated blood and
platelet count was adjusted to 250,000/1.d using homologous
platelet poor plasma. Platelet aggregation was performed as
previously described [22]. The threshold aggregation concentra-
tion (TAC) for PAF (AcGEPC; Sigma Chemical Co., St. Louis,
MO, USA), defined as the minimum amount of PAF required for
an irreversible aggregation within five minutes, was obtained.
Renal function tests
Urinary proteins were measured using a routine sulfosalicylic
acid precipitation method. Serum creatinine was measured by
kinetic Jaffé chromogen reaction. Creatinine clearance was calcu-
fated using the formula: urine creatinine (mol1liter) X urine
volume (ml/min)/serum creatinine (mol/liter). Serum urea was
measured by urease-enzymatic method using Paramax Analytical
System (Baxter, Irvine, CA, USA).
Serum immunology
Serum complement (C3 and C4) were measured by scattered
light turbidity in a nephelometer (BNA Nephelometer, Behring-
werke AG Diagnostica, Marburg, Germany). The total hemolytic
complement (CH1) was measured by the antibody-coated eryth-
rocyte hemolytic method and expressed as lytic units of comple-
ment. Antibodies to double-stranded DNA antibodies (ds-DNA
binding activity) were measured in sera using the Farr ammonium
sulphate precipitation technique.
Flow cytometly studies
Lymphocyte subsets were determined using single, dual and
three-color monoclonal antibody (MoAb) combinations. The
following MoAb were used: CD3, CD4, CD8, CD14, CD19,
CD25, CD29, CD45 (Coulter Electronics, Miami, FL, USA),
CD5, CD 16, CD56 (Becton Dickinson, Mountainview, CA, USA),
and CD11b, which recognizes C3bi receptors (AMAC Inc., West-
brook, ME, USA). Whole blood samples were incubated with
MoAbs for 30 minutes at 4°C. The red cells were then lysed using
Immunoprep reagents (Coulter Electronics), washed in phos-
phate buffered saline containing 1% bovine serum albumin,
resuspended and analyzed by flow-cytometry (Coulter Electron-
ics). Lymphocyte and neutrophil populations were identified by
light scatter characteristics (side scatter vs. forward angle light
scatter). Log fluorescence data were collected in single and dual
parameter histograms using the standard instrument filter config-
uration and analysis package (positive regions and quad stat).
Statistical analysis
Serial data for each patient from baseline through to the post
five-week washout period enabled the use of repeated measures
analysis of variance (ANOVA), which if significant was followed
by Bonferroni t-tests to discern the sources for the statistical
differences. A value of P  0.05 was regarded statistically signif-
icant. The data in the manuscript represent mean SEM.
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Table 2 Dietaiy fat and protein intake
4 Weeks 4 Weeks 4 Weeks
post-15 g post-30 g post-45 g 5 Weeks
flaxseed/ flaxseedl flaxseed/ of washout
Baseline day day day period
Fat intake 72 6 86 14 85 8 80 7 60 5
giday
Protein intake 63 9 67 7 74 6 65 6 56 7
giday from
dieta,y records
PCRg/day 70±9 62±8 66±8 70±8 60±9
based on
urea kinetics
The values include protein (25%) and fat (40%) contributions from
flaxseed actually consumed.
There was no significant difference in intake for any of the dietary
components over the study period.
There was no significant difference between protein intake based on
dietary records vs. PCR based on urea kinetics.
Results
Patients
Eight of nine patients completed the study. One dropped out
after the first four weeks of the study due to scheduling difficulties
at his work place. Three subjects experienced difficulty ingesting
the 15 g flaxseed three times daily (45 g total dose) due to
increased laxation. All patients tolerated well the 15 g and 30 g
flaxseed dosage, either mixing it with orange or tomato juice or as
a cereal topping. No patient required a change in their medica-
tions during the 17 weeks of the study.
Dietary intake assessment
The three-day dietary intake records showed no change in the
intake of total calories, protein, fat, cholesterol, and saturated,
monounsaturated and polyunsaturated fatty acids. The PCR
calculations based on urea generation confirmed no change for
protein intake determined from the dietary records. Table 2
provides the data for fat, protein intake, and PCR (glday).
Compliance
Compliance was excellent for the flaxseed dosage of 15 g/day
(15 1 g) and 30 g/day (31 3 g). However, at the 45 g/day
dosage the measurement was 43 10 g, indicating some variabil-
ity as evidenced by three of the patients reporting difficulty in
complying with the 45 glday dose due to increased taxation. This
pattern of compliance was confirmed by the increase of the
a-linolenic acid levels in the serum phospholipid from the base-
line to four-weeks post-15 g flaxseed, followed by a statistically
significant increase with the 30 g/day dosage, and a moderate
decline at the 45 g/day dosage, with a return to baseline value after
the five-week washout period (Table 3). Eicosapentenoic acid
(EPA) as well as the ratio of n3/n6 fatty acids also increased with
all of the flaxseed doses; however, the linoleic acid and the
arachidonic acid levels were unchanged (Table 3), which is in
accord with the subjects not altering their diets while taking the
flaxseed.
SLE Disease Activity Index
The SLEDAI scores ranged from 9 to 11 and were unchanged
throughout the study.
Blood pressure
The mean blood pressure was unchanged throughout all phases
of the study (Table 4). None of the patients were on, or required
any anti-hypertensive treatment.
Plasma lipids
The flaxseed exerted a significant cholesterol lowering effect at
30 glday, reducing the total cholesterol by 11% and the LDL
cholesterol by 12% (Table 5). This effect was sustained over the
four weeks of 45 g/day dose (9% for total and 10% for LDL
cholesterol) and the five-week washout period (7% for total and
11% for LDL cholesterol), indicating a prolonged lipid lowering
effect.
Rheology
Whole blood viscosity (WBV) was significantly reduced from a
baseline of 3.03 0.14 to 2.47 0.07 at the 30 g/day dose level.
This reduction in WBV was significantly maintained following the
five-week washout period at 2.52 0.11, indicating that the
flaxseed was still exerting an effect. Red cell flexibility increased
with the 30 g/day flaxseed (20.1 1.9) but this did not achieve
statistical significance compared to baseline value (19.7 1.7).
Platelet aggregation to PAF
The TAC of PAF was increased with 15 g (35.9 5.5 tg), 30 g
(27.1 7.4 g) or 45 g (25.4 9.3 g) of flaxseed compared to
baseline value of 16.1 6.4 g PAF. At the end of the five-week
washout period the TAC approximated the baseline value (17.9
5.9 pg).
Renal function tests
Serum creatinine was significantly reduced with the 30 and 45
day flaxseed dose with a return towards pre-treatment values
following the five-week washout period. The creatinine clearance
reflected this improvement, rising with increasing flaxseed doses
(Table 4). The serum urea were unchanged. Urinary protein
declined with 15 g and 30 g, and rose slightly with 45 g dose, but
returned to baseline level post-washout period (Table 4). Three
patients with the baseline proteinuria of > 1 g/24 hr showed
marked reduction, particularly by the end of the 30 g/day dose
(from 1.2, 2.5, 6.6 to 0.4, 1.8, 1.1 g/24 hr, respectively).
Serum immunology
Complement C4 and anti-DNA antibody titer were unchanged
throughout the study period. There was a trend towards a rise in
C3 level during flaxseed dosing, with a significant decline follow-
ing five-weeks of washout period (Table 6). CH100 levels rose with
45 g of flaxseed which persisted through the washout period.
Flow cytometty studies
No significant alterations were observed with flaxseed dosing in
total T helper (CD3+/CD4+), helper inducer (CD4+/CD29+),
suppressor inducer (CD4+/CD45RA+) subsets, natural killer
cells (CD3-/CD16+ and/or CD56+) or cytotoxic T cells (CD3+/
CD16+ and/or CD56+). There was a reduction in CD11b expres-
sion on neutrophils based on mean channel fluorescence (MCF)
during the 30 g/day flaxseed dosing (6.5 0.6) compared to
baseline (11.5 1.9) and the post-five-week washout period (13.5
2.3).
Baseline
Linoleic acid 16.50 0.81
(18:2n6)
Arachidonic acid 9.53 0.44
(20:4n6)
a-Linolenic acid 0.18 0.02
(18:3n3)
Eicosapentaenoic 0.93 0.08
acid (20:5n3)
Docosapentaenoic 0.72 0.07
acid (22:5n3)
Docosahexaenoic 3.18 0.21
acid (22:6n3)
Ratio: 0.17 0.01
n3/n6 fatty acids
a Significantly different from baseline
b Significantly different from 5 week post-washout period
Mean blood pressure
mmHg
Proteinuria
mg124 hr
Serum creatinine
pinol/liter
Creatinine clearance
mi/mm
Serum urea
mmol/liter
Only standing BP is given, since there was no difference between standing and supine BP.
Proteinuria was non-normally distributed; geometric means and ranges in the parentheses are given.
For serum creatinine, creatinine clearance and serum urea data represent mean SCM.
a Significantly different from baseline
4 Weeks
post-15 g
fiaxseed/day
6.23 0.43
1.56 0.22
3.83 0.43
0.84 0.10
1.76 0.22
4 Weeks
post-45 g
flaxseed/day
5.79 0.8a
1.48 0.23
3.48 0.37
0.81 0.15
1.56 0.23
5 Weeks
of washout
period
5.90 0.40
1.52 0.21
3.45 0.39
0.91 0.10
1.48 0.24
Discussion
Systemic lupus erythematosus is an autoimmune disease with a
bi-modal mortality pattern punctuated by early inflammatory and
late atherosclerotic events [26—28]. The potential of flaxseed to
alter immune, inflammatory and atherosclerotic events coupled
with our findings in murine lupus [8, 9] led us to construct a dosing
study in patients with lupus nephritis. This study provides only
preliminary evidence for an effect of flaxseed on the disease
process since the duration is short and patients are used as their
own controls.
Flaxseed was well tolerated at 15 and 30 g/day, and this was
corroborated by compliance measures with sachet counts as well
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Table 3. Select fatty acid contents of serum phopsholipids (mean SCM)
4 Weeks 4 Weeks
post-is g post-30 g
____________________________________
flaxseed/day fiaxseed/day
16.81 0.67 16.11 0.25
8.96 0.75 9.03 0.33
0.25 0.04 0.38 004ab
1.01 0.08 1.28 022b
0.79 0.05 0.82 0.07
3.17 0.14 3.22 0.01
0.25 0.02a 0.28 002a,b
4 Weeks
post-45 g
flaxseed/day
16.59 0.57
9.18 0.43
0.30 0.03
1.25 008b
0.93 0.07
3.51 0.16
0.25 0.ola
5 Weeks
of washout
period
17.12 0.53
8.66 0.51
0.21 0.04
0.80 0.08
0.69 0.06
3.27 0.15
0.21 0.01
Baseline
109 4
657
(154; 2810)112 15
81 18
6.78 0.92
Table 4. Blood pressure and renal physiology
4 Weeks 4 Weeks
post-15 g post-30 g
fiaxseed/day fiaxseed/day
105±4 106±4
578 462
(189; 1764) (170; 1256)98±14 96±12a
90±20 90±18
7.21 0.98 7.78 1.12
4 Weeks
post-45 g
fiaxseed/day
105 3
503
(147; 1722)90 13
101 23
7.35 1.09
5 Weeks
of washout period
109 4
663
(142; 3098)104 17
92 15
7.25 1.59
Baseline
Total cholesterol 6.37 0.45
mmoi/liter
HDL-cholesterol 1.58 0.24
mmol/liter
LDL-cholesterol 3.88 0.41
mmol/iiter
VLDL-cholesterol 0.93 0.14
mmoi/liter
Triglycerides 1.62 0.25
mmoi/iiter
a Significantly different from baseline
Table 5. Plasma lipids (mean SEM)
4 Weeks
post-30 g
____________
fiaxseed/day
5.64 0.36a
1.51 0.26
3.42 0.35
0.71 0.11
1.58 0.25
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Table 6. Serum immunology (mean 5EM)
4 Weeks 4 Weeks 4 Weeks
post-iS g post-30 g post-45 g 5 Weeks
flaxseed/ flaxseed/ flaxseed/ of washout
Baseline day day day period
C3 610 69 657 8&' 656±61" 649 73" 560±65
mg/liter
C4 196±36 205±40 202±34 213±42 182±33
mg/liter
CH100 83±12 90±15 98±17 63±14a 67±o9a
U/mI
DNA-b 125±42 137±45 140±39 133±37 123±38
lU/mi
a Significantly different from post-30 g flaxseed/day
"Significantly different from 5 weeks post-washout
as the increase of a-linolenic acid levels in serum phospholipids.
However, the 45 g/day dose of fiaxseed was not well tolerated due
to increased laxation and was associated with increased variability
in compliance as well as a decrease in a-linolenic acid levels
compared to the 30 glday dose. Dietary enquiry and the protein
catabolic rate (PCR) determination indicated that patients did not
alter their diet, particularly protein intake, during the study period
(Table 2), which was in keeping with the constancy of serial
linoleic and arachidonic acid levels (Table 3).
Total and LDL cholesterol levels were significantly decreased
with the 30 and to a lesser extent with 45g,'day flaxseed, and this
effect persisted after the five week washout. The lipid lowering
effect of fiaxseed was not associated with a change in total fat,
cholesterol or saturated fatty acid intake based on the dietary
enquiry. The fiaxseed is composed of 38 to 40% fat of which 50%
is a-linolenic acid, and 26 to 33% dietary fiber and mucilage
[29—31j. Thus, it is not clear whether either, or both, are respon-
sible for the significant reduction in LDL cholesterol levels.
Hypercholesterolemia is a major feature of the dyslipidemia of
SLE [32]. The marked hypocholesterolemic effects of the flaxseed
may reduce not only the accelerated atheromatous vascular
disease but also the renal tissue scarring in patients with lupus
nephritis [33—35]. The observed lipid lowering effects, coupled
with the significant reduction in whole blood viscosity with 30
glday fiaxseed, suggests the potential for a major reduction in the
incidence of coronary artery disease and stroke in this high risk
patient population [26—28, 36]. In this regard it is important to
note that an increased intake of a-linolenic acid-rich diet, and the
resultant increase in a-linolenic acid, EPA and n3/n6 ratio in
serum phospholipids (also observed in the present study; Table 3)
significantly decreased cardiac death and the non-fatal myocardial
re-infarction in patients with coronary heart disease [37].
Renal function, assessed by serum creatinine, creatinine clear-
ance and urinary protein measurements, was surprisingly altered
in the short duration of the study. The significant decline in serum
creatinine coupled with an increase in creatinine clearance, and a
decrease in proteinuria does not suggest a pharmacologic action
of the flaxseed on renal hemodynamics. Theoretically, this finding
is more compatible with a direct alteration in glomerular base-
ment membrane properties which would be associated with
increased filtration and improved permselectivity [38]. The reduc-
tion in serum viscosity which persisted after five weeks of the
washout period is similar to our findings with fish oil [6]. The
reduction in whole blood viscosity could potentially contribute to
a decrease in glomerular capillary permeability and the conse-
quent reduction in proteinuria [39}.
The flaxseed ingestion was associated with an increase in the
amount of PAF required to cause platelet aggregation and this
effect disappeared following the five week washout. We had
previously documented the ability of flaxseed to inhibit PAF-
induced platelet aggregation in mice [8]. Flaxseed is the richest
natural source of lignans, and produces 75- to 800-fold more
mammalian lignans than 66 other plant foods in vegetarian diets
[40]. Lignans are a group of substances containing a dibenzyl
butane skeleton that produces specific reversible and competitive
inhibition of PAF [13].
The fiaxseed dietary supplementation did not alter the SLEDAI
in the subjects nor the mean blood pressure, which is also
compatible with our findings in previous studies of omega-3 fatty
acids (fish oil) in lupus nephritis [6, 7]. We observed rising levels
of C3 relative to the flaxseed dose. The reduction in CD11b
expression (a measure of C3bi receptors) on the neutrophil with
30 glday dose of fiaxseed was also noted. Other immune serologic
parameters, as well as T cell markers were largely unchanged by
the flaxseed dosing. Flaxseed oil has been shown in 10 healthy
volunteers to suppress the proliferation of peripheral mononu-
clear cells when stimulated by phytohemagglutinin or concanavo-
lin A in the delayed hypersensitivity response to seven recall
antigens [11]. However, the fiaxseed oil did not produce a change
in the number of helper, suppressor or total T and B cells in
peripheral blood in that study [11], which is in keeping with our
flow cytometry data.
We conclude that 30 g/day of fiaxseed is well tolerated by
patients with SLE nephritis, and it exerts significant effects on
renal function, plasma lipids, blood viscosity and complement C3
levels. These preliminary findings of the dosing study are of
interest and may serve to stimulate larger control studies to
confirm or refute fiaxseed's potential as a treatment for patients
with lupus nephritis.
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